Kastle Therapeutics, LLC

Novartis AG ’s planned acquisition of The Medicines Co. rests on one product: inclisiran, a small interfering RNA that inhibits synthesis of PCSK9, thereby reducing production low-density lipoprotei

Ionis Pharmaceuticals Inc. has been in it for the long haul, developing antisense drugs for more than 25 years. But now partnered and independently-owned drugs are in late-stage development and the

South Korea's OliPass Corp. may not be a mainstream antisense drug company, but it has strong ambitions and the confidence to become a top global oligonucleotide therapeutics company with its plat

IN VITRO DIAGNOSTICS Mergers & Acquisitions Luminex Corp. Nanosphere Inc. Luminex Corp. is paying $77mm ($1.70 per share; a 63% premium) in cash to acquire molecular diagnostics firm Nanosphere